Dienstag, 15. Juni 2021
Navigation öffnen
Imfinzi NSCLC
Imfinzi NSCLC

A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis



Februar 2021

Letztes Update:

Belantamab mafodotin

Indikation (Clinical Trials):
Immunoglobulin Light-chain Amyloidosis, Amyloidosis


Erwachsene (18+)

Phase 2

European Myeloma Network



Efstathios European Myeloma Network (EMN), MD
Phone: +31107033123
E-Mail: sarah.lonergan@emn.life
» Kontaktdaten anzeigen

(3 von 6)

Alle anzeigen


Brief Summary:

This is an open-label, multicenter, Phase 2 study in subjects with previously treated

patients with light chain (AL) amyloidosis in need for therapy.

Approximately 35 subjects will receive therapy with belantamab mafodotin. Subject

participation will include a Screening Phase, a Treatment Phase, a Post-Treatment Observation

Phase, and a Long-term Follow-up Phase.

A safety run-in will be conducted in 6 subjects treated with belantamab mafodotin for at

least 1 cycle.

According to the two-stage statistical design of the study, an interim analysis of efficacy

will occur. If after 15 patients have been enrolled at least 3 complete or very good partial

responses have been recorded, the accrual will continue until all planned patients have been



Inclusion Criteria:

1. Diagnosis of AL amyloidosis, confirmed by histology and typed with

immunohistochemistry, immunoelectron microscopy or mass spectrometry or if not

available, for patients with biopsy confirmed amyloidosis and cardiac involvement

alone, if they also have a negative PYP- or DPD-Tc99m bone scan.

2. Previous systemic therapy for AL amyloidosis

3. Patients must be ≥ 18 years of age.

4. ECOG performance status 0, 1 or 2.

5. Mayo stage 1 or Mayo stage 2 or Mayo stage 3A1-3 defined as both cTnT < 0.035 ng/mL

(or in place of cTnT the cTnI < 0.10 ng/mL or high sensitivity Troponin T < 54 ng/L)

AND simultaneous NT-proBNP ≤ 332 ng/L, OR EITHER above threshold, or BOTH above

threshold but with NTproBNP < 8500 ng/L (stage 3A disease)

6. Supine systolic blood pressure ≥ 90 mmHg

7. Measurable disease defined by at least one of the following:

1. serum free light chain (FLC) ≥2.0 mg/dL (20 mg/L) with an abnormal kappa:lambda

ratio or the difference between involved and uninvolved free light chains (dFLC)

≥2mg/dL (20 mg/L).

2. presence of a monoclonal spike that is ≥0.5 gr/dl.

8. Symptomatic organ involvement (heart, kidney, liver/GI tract, peripheral nervous


9. Patient must have adequate organ function, defined as follows:

System Laboratory Values


Absolute neutrophil count (ANC) ≥1.5 X 109/L Hemoglobin ≥8.0 g/dL Platelets ≥75 X



Total bilirubin ≤1.5X ULN (Isolated bilirubin ≥1.5xULN is acceptable if bilirubin is

fractionated and direct bilirubin <35%) ALT ≤2.5 X ULN Renal: eGFR ≥30 mL/min/ 1.73 m2

Cardiac:LVEF (Echo) Clinically asymptomatic patients with ECHO confirmed LVEF ≥25%

10. Written informed consent in accordance with local and institutional guidelines.

11. Female patients: contraceptive use should be consistent with local regulations

regarding the methods of contraception for those participating in clinical studies

A female patient is eligible to participate if she is not pregnant or breastfeeding,

and at least one of the following conditions applies:

- Is not a woman of childbearing potential (WOCBP) OR

- Is a WOCBP and using a contraceptive method that is highly effective (failure

rate of <1% per year), preferably with low user dependency (as described in

Appendix 3), during the intervention period and for at least four months after

the last dose of study intervention and agrees not to donate eggs (ova, oocytes)

for the purpose of reproduction during this period. The investigator should

evaluate the effectiveness of the contraceptive method in relationship to the

first dose of study intervention.

A WOCBP must have a negative highly-sensitive serum pregnancy test (as required by

local regulations) within 72 hours before the first dose of study intervention.

The investigator is responsible for review of medical history, menstrual history, and

recent sexual activity to decrease the risk for inclusion of a woman with a nearly

undetected pregnancy.

Nonchildbearing potential is defined as follows (by other than medical reasons):

- ≥45 years of age and has not had menses for >1 year,

- Patients who have been amenorrhoeic for <2 years without history of a

hysterectomy and oophorectomy must have a follicle stimulating hormone value in

the postmenopausal range upon screening evaluation,

- Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation.

Documented hysterectomy or oophorectomy must be confirmed with medical records of

the actual procedure or confirmed by an ultrasound. Tubal ligation must be

confirmed with medical records of the actual procedure.

12. Male Patients : contraceptive use should be consistent with local regulations

regarding the methods of contraception for those participating in clinical studies.

Male Patients are eligible to participate if they agree to the following during the

intervention period and for 6 months after the last dose of study treatment to allow

for clearance of any altered sperm:

• Refrain from donating sperm

PLUS either:

• Be abstinent from heterosexual intercourse as their preferred and usual lifestyle

(abstinent on a long term and persistent basis) and agree to remain abstinent.


• Must agree to use contraception/barrier as detailed below: Agree to use a male

condom, even if they have undergone a successful vasectomy, and female partner to use

an additional highly effective contraceptive method with a failure rate of <1% per

year as when having sexual intercourse with a WOCBP who is not currently pregnant.

13. All prior treatment-related toxicities (defined by National Cancer Institute- Common

Toxicity Criteria for AEs (NCI-CTCAE), version 5, corneal toxicities are defined

according to the Keratopathy Visual Activity [KVA] scale) must be ≤ Grade 1 at the

time of enrolment except for alopecia.

14. Patients must be able to understand the study procedures and agree to participate in

the study by providing written informed consent

Exclusion Criteria:

1. Presence of non-AL amyloidosis.

2. Presence of lytic bone lesions or active myeloma with hypercalcemia, cast nephropathy,

anemia due to marrow infiltration or extramedullary disease.

3. Previously untreated disease: patients must have had at least 2 cycles of therapy

directed against the plasma cell clone; however, patients that have received high dose

therapy with melphalan as their only therapy are eligible for the study.

4. Previous exposure to anti-BMCA agents

5. Cardiac stage IIIB disease: both cTnT > 0.035 ng/mL (or in place of cTnT the cTnI >

0.10 ng/mL or high sensitivity Troponin T > 54 ng/L) AND simultaneous NT-proBNP >8500


6. Known repetitive ventricular arrhythmias on 24h Holter Electrocardiogram (ECG) in

spite of anti-arrhythmic treatment. Patients must not have evidence of cardiovascular

risk including any of the following:

- Evidence of current clinically significant uncontrolled arrhythmias, including

clinically significant ECG abnormalities such as 2nd degree (Mobitz Type II) or

3rd degree atrioventricular (AV) block.

- History of myocardial infarction, acute coronary syndromes (including unstable or

uncontrolled angina), coronary angioplasty, or stenting or bypass grafting within

three (3) months of Screening.

- Class III or IV heart failure as defined by the New York Heart Association

functional classification system [NYHA, 1994]

- Severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or

electrocardiographic evidence of acute ischemia or Grade 3 conduction system

abnormalities unless patient has a pacemaker.

- Uncontrolled hypertension or hypotension (i.e., supine SBPN < 90 mmHg despite

supportive therapy with midodrine)

7. Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to

Cycle 1 Day 1.

8. Pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14

days prior to Cycle 1 Day 1.

9. Current corneal epithelial disease except mild changes in corneal epithelium.

10. Current unstable liver or biliary disease defined by the presence of large volume

ascites requiring paracentesis, encephalopathy, coagulopathy, hypoalbuminemia (except

due to AL related nephrotic syndrome), esophageal or gastric varices, persistent

jaundice, or cirrhosis. Note: Stable non-cirrhotic chronic liver disease (including

Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement due to AL

amyloidosis is acceptable if otherwise meets entry criteria.

11. Presence of active renal condition (infection, requirement for dialysis or any other

condition that could affect the patient's safety) unrelated to AL amyloidosis.

Patients with isolated proteinuria resulting from AL are eligible, provided they

fulfil other inclusion criteria

12. Patients must not use contact lenses while participating in this study.

13. Patients must not be simultaneously enrolled in any interventional clinical trial.

14. Use of an investigational drug or approved systemic anti-myeloma therapy (including

systemic steroids) within 14 days or five half-lives, whichever is shorter, preceding

the first dose of study drug.

15. Plasmapheresis within 7 days prior to first dose of study treatment.

16. Treatment with a monoclonal antibody within 30 days of receiving the first dose of

study drugs.

17. Major surgery ≤ 4 weeks prior to initiating study treatment.

18. Any evidence of active mucosal or internal bleeding.

19. Known immediate or delayed hypersensitivity reaction or idiosyncratic reactions to

blmf or drugs chemically related to blmf, or any of the components of the study


20. Active infection requiring treatment.

21. Known HIV infection (defined by positive testing for human immunodeficiency virus

(HIV) antibodies).

22. Positive test of hepatitis B surface antigen, or hepatitis B core antibody at

screening or within 3 months prior to first dose of study treatment.

23. Positive hepatitis C antibody test result or positive hepatitis C RNA test result at

screening or within 3 months prior to first dose of study treatment.

Note: Patients with positive hepatitis C antibody due to prior resolved disease can be

enrolled, only if a confirmatory negative hepatitis C RNA test is obtained.

Note: Hepatitis RNA testing is optional and patients with negative hepatitis C

antibody test are not required to also undergo hepatitis C RNA testing.

24. Invasive malignancies other than disease under study, unless the second malignancy has

been medically stable for at least 2 years and, in the opinion of the principal

investigators, will not affect the evaluation of the effects of clinical trial

treatments on the currently targeted malignancy. Patients with curatively treated

non-melanoma skin cancer may be enrolled without a 2-year restriction.

25. Any serious and/or unstable pre-existing medical, psychiatric disorder, or other

conditions (including lab abnormalities) that could interfere with the patient's

safety, obtaining informed consent or compliance to the study procedures.

26. Patients must not be pregnant or breast-feeding


Primary outcome:

1. response rate (Time Frame - at 6 months (cycle 4)):
Complete Response (CR)/ Very Good Partial Response (VGPR)/ <50 mg/L difference between involved minus uninvolved serum free lights chains (low-dFLC) according to the consensus recommendations for AL amyloidosis treatment response criteria

Secondary outcome:

1. Adverse events (Time Frame - up to 70 days after last dose):
Rates of grade 3 or higher AEs related to blmf therapy

2. Treatment discontinuation (Time Frame - up to 1 year):
Rates of treatment discontinuation due to toxicity related to blmf

3. Dose reduction (Time Frame - up to 1 year):
Dose reduction due to toxicity of blmf therapy

4. Hematologic AEs (Time Frame - up to 70 days after last dose):
rates of any hematologic adverse events

5. Non-hematologic AEs (Time Frame - up to 70 days after last dose):
rates of any non-hematologic adverse events

6. Ocular toxicity (Time Frame - up to 1 year):
rates of adverse events of special interest

7. Overall hematologic response rates (Time Frame - 3 months, 6 months):
Complete Response (CR)/ Very Good Partial Response (VGPR)/ <50 mg/L difference between involved minus uninvolved serum free lights chains (low-dFLC)/ Partial Response (PR)

8. Organ response rates (Time Frame - 3,6,12,18, and 24 months):
Organ response rates per individual organ (heart, kidney, liver) according to International Amyloidosis Consensus Criteria

9. Duration of response (Time Frame - approximately up to 9 years):
Duration of response is defined as the time between first documentation of response (achievement of at least a PR or lowdFLC response) and PD

10. Determine time to progression (Time Frame - approximately up to 9 years):
From the date of registration to the date of first disease progression, major organ deterioration or death, whichever occurs first

11. Overall survival (Time Frame - approximately up to 9 years):
Overall Survival, measured from the date of from randomization to the date the subject's death

Geprüfte Regime

  • Belantamab mafodotin:
    Belantamab mafodotin will be administered as a monotherapy intravenously at a 2.5 mg/kg calculated dose

Quelle: ClinicalTrials.gov

Das könnte Sie auch interessieren
Startschuss für den Regensburger Leukämielauf 2017: Bürgermeisterin Gertrud Maltz-Schwarzfischer übernimmt Schirmherrschaft und die Kapelle Josef Menzl beginnt Training
© ivanko80 / Fotolia.com

Vor der Kulisse des Alten Rathauses wurde gestern (26.06.) Bürgermeisterin Gertrud Maltz- Schwarzfischer das erste Laufshirt des Regensburger Leukämielaufes 2017 von Professor Dr. Reinhard Andreesen, Vorsitzender der Leukämiehilfe Ostbayern e.V., überreicht. Mit der Übergabe des Laufshirts an das Stadtoberhaupt startet traditionell der Countdown zum größten Benefizlauf in Ostbayern, der in diesem Jahr am 15....

Weltgesundheitstag 2021: Das BürgerTelefonKrebs informiert im Kampf gegen Krebs
©Antonioguillem - stock.adobe.com

Die Medien und das Internet überfluten uns regelmäßig mit Informationen zu unzähligen Erkrankungen und Anleitungen für einen gesunden Lebensstil. Doch diese Inhalte ersetzen weder die individuelle Beratung, noch wichtige Vorsorgeuntersuchungen. Im vergangenen Jahr haben viele Bürger:innen die empfohlenen Check-ups vernachlässigt und den als nicht so wichtig empfundenen Gang zur Ärztin oder zum Arzt...

EHA 2021
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose
  • Hochrisiko-MDS und AML: Sabatolimab + Decitabin/Azacitidin zeigt in Phase-I-Studie anhaltende Remissionen bei guter Verträglichkeit
  • PNH: Neuer oraler Faktor-B-Inhibitor Iptacopan zeigt in Phase-II-Studie Wirksamkeit in der Erstlinie